GIBRALTAR BSN AGGRESSIVE FUND
January 2023

Investment Objective

To achieve consistent and above average capital appreciation over the medium to long-term by investing in companies with market capitalization of not more than RM750 million at the time of acquisition.

Investor Profile

The fund is suitable for investors who are willing to accept higher level of risk in order to obtain higher growth of their capital and have a medium to long term investment horizon.

Fund Manager

UOB Asset Management (Malaysia)

Fund Details

Unit NAV	RM3.7728
Fund Size	RM77.5 million
Inception Date	1 April 2005
Management Fee	1.50% per annum

Top 10 Holdings

Berjaya Food	8.2%
D&O	6.0%
Formosa Prosonic	5.5%
Duopharma	4.7%
Thong Guan	4.2%
Pentmaster	4.1%
Power Root	4.0%
Frontken	3.9%
SFP Tech	3.9%
Dufu Technology	3.4%

Data as at 31 December 2022

Cumulative Performance Since Inception as at 31 December 2022

Performance Table as at 31 December 2022

	1 month	3 months	6 months	YTD	1 year	3 years	5 years	Since inception
Fund	3.4%	6.3%	9.2%	-13.6%	-13.6%	25.5%	44.5%	694.3%
Benchmark	0.6%	7.3%	3.8%	-5.4%	-5.4%	-5.5%	-17.3%	82.5%

- *Benchmark: FTSE Bursa Malaysia Emas Index*
- *Source: Bloomberg & Gibraltar BSN Life Bhd*

Past performance is not indicative of future performance and the performance of the fund is not guaranteed.

Portfolio Composition as at 31 December 2022

Source: UOBAM

GIBRALTAR BSN AGGRESSIVE FUND
January 2023

Manager's Comment

For December 2022, the Fund's NAV/unit increased by 3.39%, outperforming FBM EMAS gain of 0.64%. The outperformance was mainly due to the Fund's overweight position in the industrial and technology sectors.

Global equities fell month-on-month for December, with both Developed and Emerging Markets posting losses. Broad concerns affecting investor sentiment throughout 2022 continued to play on investors' thoughts in December, including rising interest rates and economic slowdown. The U.S. Dollar Index (DXY index) dropped from 105.95 in November to 103.52 in December, while the US 10-year Treasury yield increased from 3.61% in November to 3.87% as at end December.

Traditionally, December has tended to be a positive month for the performance of the Malaysian market. This was the case in 2022 with the FBM KLCI gaining 0.4% in December. The best performing sectors were plantation, transport and healthcare while the worst performing sectors were property, construction and telecom. The index finished strongly on window dressing activities as well as positive market sentiment following the Prime Minister's win on the motion of confidence in Parliament on 19 December.

Foreign investors were net sellers at RM1.4 billion in December (vs net sell of RM282 million in November). Local institutional investors were the largest net buyers at RM1.7 billion in December (vs net buy of RM153 million in November).

Moving into 2023, we keep a cautious outlook on markets given the likelihood of slower global economy growth and increasing risks of corporate earnings downgrades.

Disclaimer
This report is for information only and is purely a product summary. Please refer to the product fact sheet available at www.gibraltarbsn.com for further details. This report shall not be reproduced, copied, circulated or forwarded either in part or otherwise to any persons howsoever without the prior written consent of Gibraltar BSN Life Berhad.

The opinions and information contained herein are based on the latest available data which is believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell any securities or financial instruments covered by this report. Gibraltar BSN Life Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Gibraltar BSN Life Berhad and/or its associated persons. Gibraltar BSN Life Berhad and/or its associated persons may from time to time have an interest in the securities or financial instruments mentioned by this report. Past Performance of the Funds mentioned in the Report is not an indication of its future performance. Investors/policy holders should rely on their own evaluation to assess the merits and risks of the investment. In considering to invest in an investment-linked fund, investors/policy holders who are in doubt on the action to be taken should consult a professional adviser. Investors/Policy holders have to take note that investments can fluctuate in value and values may fall as well as rise and an investor/policy holder may not get back the amount invested.